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ABSTRACT
There is compelling evidence that proliferating
cell nuclear antigen (PCNA), a DNA sliding clamp,
co-ordinates the processing and joining of Okazaki
fragments during eukaryotic DNA replication.
However, a detailed mechanistic understanding of
functional PCNA:ligase I interactions has been
incomplete. Here we present the co-crystal struc-
ture of yeast PCNA with a peptide encompassing
the conserved PCNA interaction motif of Cdc9,
yeast DNA ligase I. The Cdc9 peptide contacts
both the inter-domain connector loop (IDCL)
and residues near the C-terminus of PCNA.
Complementary mutational and biochemical results
demonstrate that these two interaction interfaces
are required for complex formation both in the
absence of DNA and when PCNA is topologically
linked to DNA. Similar to the functionally homo-
logous human proteins, yeast RFC interacts with
and inhibits Cdc9 DNA ligase whereas the addition
of PCNA alleviates inhibition by RFC. Here we show
that the ability of PCNA to overcome RFC-mediated
inhibition of Cdc9 is dependent upon both the IDCL
and the C-terminal interaction interfaces of PCNA.
Together these results demonstrate the functional
significance of the b-zipper structure formed
between the C-terminal domain of PCNA and Cdc9
and reveal differences in the interactions of FEN-1
and Cdc9 with the two PCNA interfaces that may
contribute to the co-ordinated, sequential action of
these enzymes.
INTRODUCTION
DNA ligases seal nicks in double-stranded DNA.
The budding yeast Saccharomyces cerevisiae contains
two diﬀerent DNA ligases encoded by the CDC9 and
DNL4 genes that are homologs of human DNA ligases
I and IV, respectively (1–6). Dnl4 appears to function
only in the repair of DNA double strand breaks by
non-homologous end joining (3,4,6). In contrast, genetic
and biochemical studies have shown that Cdc9 DNA
ligase is multifunctional. It is an essential DNA replica-
tion protein that joins Okazaki fragments generated
during lagging strand DNA synthesis (2,7). When grown
at the permissive temperature, temperature-sensitive
cdc9 strains exhibit sensitivity to killing by various DNA
damaging agents, implicating Cdc9 DNA ligase in
DNA repair (2,8). In accord with this phenotype, extracts
from the cdc9 mutant strains are defective in the
completion of both base and nucleotide excision repair
(9). Finally, two polypeptides are generated from the
CDC9 gene by alternative translation initiation (10).
The shorter polypeptide participates in the nuclear
transactions described above whereas the longer polypep-
tide is targeted to the mitochondria and plays a critical
role in mitochondrial DNA metabolism (10).
The participation of human DNA ligase I in DNA
replication and DNA repair is mediated by an interaction
with proliferating cell nuclear antigen (PCNA) (11,12).
PCNA belongs to the family of DNA sliding clamps,
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phage T4 gp45. These ring proteins encircle the DNA
duplex and serve as processivity factors for DNA
polymerases (13–16). Despite only sharing 35% amino
acid sequence identity, the overall structures of the
human and yeast PCNA (Pol30) homotrimers are super-
imposable and closely resemble the dimeric b clamp of
E. coli (17–19).
A rapidly growing number of PCNA interacting
proteins have been identiﬁed, implicating PCNA in
functions as varied as DNA replication, DNA repair,
cell cycle checkpoint control, chromatin assembly and
apoptosis (as reviewed in (16,20–23)). Many of these
proteins contain a conserved motif called the PCNA
interacting protein (PIP) box that interacts with the inter-
domain connector loop (IDCL) of PCNA. In human
DNA ligase I, the PIP box is located at the N-terminus
(residues 2–9) (12) whereas in Cdc9 the PIP box is located
at residues 38–45 (24,25).
Since PCNA is a homotrimer, it is possible that
complexes containing up to three PCNA-interacting
proteins can be assembled on a single PCNA ring.
Recently, it has been shown that each of the subunits
in a human PCNA trimer can simultaneously bind to a
diﬀerent ﬂap endonuclease 1 (FEN-1) molecule, a DNA
structure-speciﬁc endonuclease involved in Okazaki frag-
ment processing (26). By contrast, the complex formed
between human DNA ligase I and PCNA topologically
linked to DNA contained only one DNA ligase I molecule
per PCNA trimer (27). This result, together with the size
and shape of the ring formed by the catalytic domain of
DNA ligase I when it encircles nicked DNA (28), suggests
that the binding of one molecule of DNA ligase I to a
PCNA trimer occludes the other IDCL-binding sites.
In accord with this model, the binding of yeast Cdc9 and
FEN-1 (Rad27) to a yeast PCNA (yPCNA) trimer appear
to be mutually exclusive (25). Moreover, genetic instability
induced by Cdc9 overexpression is dependent upon a
functional PIP box, presumably because Cdc9 sequesters
yPCNA molecules away from other PCNA interacting
proteins, thereby disrupting the PCNA-dependent
co-ordination of Okazaki fragment processing (25).
Although the IDCL of PCNA mediates the binding
to FEN-1 in the absence of DNA (29,30), amino acid
residues in the C-terminal domain of yPCNA are required
to stimulate the ﬂap cleavage activity of FEN-1 (Rad27)
(31). In a recent X-ray structure of a peptide containing
the PIP box of archaeal FEN-1 complexed with an
archaeal PCNA, amino acid residues immediately
adjacent to the PIP box form a b-zipper structure with
residues in the C-terminal domain of PCNA, suggesting
that these contacts hold FEN-1 on the PCNA ring
in a suitable position to cleave the DNA single strand
ﬂap (32).
Unlike FEN-1 (31–34), human DNA ligase I catalytic
activity is not stimulated by PCNA (27,33). However,
human DNA ligase I interacts with and is inhibited
by replication factor C (RFC), a heteropentameric
complex that loads PCNA onto DNA (35). Interestingly,
the presence of PCNA alleviates inhibition by RFC
but only if the PIP box of DNA ligase I is functional (35).
This suggests that pairwise interactions among RFC,
PCNA and DNA ligase I may co-ordinate the ligation
step that joins Okazaki fragments and completes
DNA excision repair events. However, these pairwise
interactions have not been completely deﬁned at high
resolution.
Here, we present the co-crystal structure of yPCNA
with a peptide encompassing the PIP box of Cdc9.
As FEN-1 (Rad27) generates the ligatable nick that is
sealed by Cdc9 DNA ligase, the striking similarities of the
complexes formed by PCNA with the PIP box of Cdc9
and with the FEN-1 PIP box region indicate that these
interactions have signiﬁcant functional implications (32).
Structural, mutational and biochemical results indicate
that the Cdc9 PIP box region makes physical and
functional contacts with both the IDCL and C-terminal
domain of yPCNA. In addition, we show that interplay
among the replicative DNA ligase, sliding clamp and
clamp loader is conserved in eukaryotes (35) and that
residues within the C-terminal domain of PCNA are
critical for these functional interactions.
MATERIALS AND METHODS
OverexpressionandpurificationofyPCNAforcrystallization
yPCNA was puriﬁed following overexpression in E. coli
BL21 (DE3) cells (Invitrogen) containing the plasmid
pT7-PCNA essentially as described (36). Brieﬂy, E. coli
cells harboring pT7-PCNA were grown at 378Ct oa n
OD600 of 0.35 in Luria Broth (LB) media supplemented
with ampicillin (100mg/ml), and yPCNA expression was
induced by the addition of 1mM isopropylthiogalactoside
(IPTG) to the media followed by incubation for 3h at
378C. Cells were lysed on ice for 1h with lysozyme in
25mM Tris-HCl (pH 7.5), 100mM NaCl, 0.01% NP40
and 1mM dithiothreitol (DTT) plus protease inhibitors
(5mM each of pepstatin, leupeptin and chymostatin
and 0.5mM p-methylphenylsulfonyl ﬂuoride), followed
by sonication. yPCNA was puriﬁed from the cleared lysate
by sequential steps of Q-sepharose, SP-sepharose, hydro-
xylapatite and phenyl-sepharose column chromatography.
Next, yPCNA-containing fractions were pooled and
dialyzed overnight against 25mM Tris-HCl (pH 7.4),
1mM EDTA, 200mM NaCl, 0.01% NP-40, 10% glycerol,
5mM DTT plus protease inhibitors. After loading
onto a Q-sepharose column, yPCNA was eluted with a
200–700mM NaCl gradient. Fractions containing yPCNA
were dialyzed overnight against 20mM Tris-HCl (pH 7.5),
100mM NaCl, 1mM EDTA, 5mM 2-mercaptoethanol
and then concentrated using a Centricon-10 column
(Amicon). Approximately 41mg of 495% homogenous
yPCNA were puriﬁed from 3l of culture. The ﬁnal
concentration of yPCNA was determined by absorbance
at 280nm to be 68mg/ml.
Crystallization, datacollection and refinement
ofthe yPCNA-Cdc9 peptide complex
A peptide corresponding to the PCNA-binding region
of Cdc9 (AGKKPKQATLARFFTSMKNKPT, residues
32–53) was synthesized by the Protein Core Facility at
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dissolved in 20mM Tris-HCl (pH 8.0), 50mM NaCl to
a ﬁnal concentration of 1.2mM. The yPCNA-peptide
complex was formed by mixing 1mM yPCNA with
1.2mM peptide in 20mM Tris-HCl (pH 7.5), 100mM
NaCl, 1mM EDTA, 5mM 2-mercaptoethanol. After the
addition of an equal volume of precipitant (1.6M
(NH4)2SO4, sodium citrate pH 5.6), crystals were grown
by hanging-drop vapor diﬀusion at 218C over a period
of 1 week. The crystals belonged to the space group I23
with unit cell dimensions a¼b¼c¼139.
Single crystals of the yPCNA-peptide complex were
harvested from the drop, and soaked in mother
liquor supplemented with 20% ethylene glycol for
10–20s. X-ray diﬀraction data were obtained from a
single crystal cooled to 100K at beamline 9–1 of the
Stanford Synchrotron Radiation Laboratory (SSRL).
The structure of the yPCNA–peptide complex was
determined by molecular replacement with the program
AMoRe (37), using the structure of yPCNA (PDB code
1PLQ, (18)) as a starting model. To reduce model bias,
the IDCL (residues 121–132) and the C-terminal 8 residues
(residues 251–258) of yPCNA were deleted from the
starting model prior to phasing. Molecular replacement
with AMoRe yielded a single solution with a correlation
coeﬃcient of 48.6 and an R-factor of 40.8 using data from
4–8A ˚ . The next best solution had a correlation coeﬃcient
of 35.5 and an R-factor of 45.5. Rigid-body, restrained
B-factor reﬁnement, followed by simulated annealing and
grouped B-factor reﬁnement was carried out in CNS (38).
The Cdc9 peptide and the IDCL and C-terminus of
yPCNA were clearly visible in  A-weighted Fo-Fc maps
contoured at 2.5 or 3 . These maps were suﬃcient to
model 11 of the 22 residues of the Cdc9 peptide,
the entire IDCL region (residues 121–132) and all but
the 3C-terminal residues of PCNA (residues 256–258),
which are not included in the model. After initial model-
building in Xﬁt (39), the structure was reﬁned by cycles
of maximum-likelihood restrained reﬁnement with TLS
against all data to 2.8A ˚ resolution with REFMAC5 (40)
followed by manual building in Xﬁt. For TLS reﬁnement,
the peptide residues were deﬁned as a separate group from
yPCNA. The electron density for the reﬁned structure
clearly shows the position of the peptide backbone, and
critical side-chains such as Gln38, Leu41 and Phe44.
However, no electron density was observed for the side
chains of residues Lys35 and Lys37. The side-chain of the
ﬁnal conserved Phe of the Cdc9 peptide (Phe45) is weak,
but is present at 2.5  contour level. The current model
of the complex is reﬁned to a crystallographic R-value
of 0.247 (R-free¼0.285), with 90.5% of the residues in
the most preferred phi/psi regions and no residues in the
generously allowed or disallowed regions. Coordinates
and structure factors for the Cdc9 peptide:PCNA complex
have been deposited in the RCSB protein data bank
with accession code 2OD8.
Proteins and antibodies
Untagged wild-type yPCNA and the mutant versions,
pcna-79 and pcna-90 were expressed in and puriﬁed
from E. coli cells by a modiﬁed version of a published
puriﬁcation scheme (41). Brieﬂy, an overnight culture
(10ml) of M15 cells (Qiagen) harboring the PCNA
expression plasmid pQE16-PCNA was diluted in 1l of
LB containing ampicillin and kanamycin and grown
at 378C. At an OD600 of 0.8, 0.5mM IPTG was added
and incubation continued for 3h at 378C. Cells were
harvested and then resuspended in HEG buﬀer (30mM
HEPES-NaOH (pH 7.5), 0.5mM EDTA, 10% glycerol,
0.01% NP-40, 1mM DTT, 5mM each of proteinase
inhibitors pepstatin, leupeptin, chymostatin and 0.5mM
p-methylphenylsulfonyl ﬂuoride) containing 200mM KCl
and lysed by sonication. The mutant versions of yPCNA,
pcna-79 and pcna-90 (30) were expressed in the strain
BL21(DE3). Wild-type and mutant versions of PCNA
were puriﬁed from cleared lysates by Q sepharose
(GE Healthcare), hydroxyapatite (Bio-Rad), Mono Q
and Superdex 200 (GE Healthcare) column chromato-
graphy. Approximately 10mg of 495% homogeneous
PCNA was obtained from a 1-l culture.
Glutathione-S-transferase (GST) fusion proteins of
wild-type Cdc9 and a PIP box mutant version
PIP box (FF44,45AA) were expressed and puriﬁed as
described previously (35). The expression of his-tagged
versions of wild-type Cdc9 and the PIP box mutant in
E. coli M15 cells was induced by the addition of 0.5mM
IPTG at an OD600 of 0.8 followed by growth for 4h
at 258C. Harvested cells were resuspended in HEG
buﬀer containing 100mM KCl and lysed by sonication.
The his-tagged versions of Cdc9 were puriﬁed from the
cleared lysates to near homogeneity by SP Sepharose,
Source S, Mono Q and Mono S (GE Healthcare) column
chromatography.
Yeast RFC (yRFC) was expressed in and puriﬁed
from E. coli cells as described previously (42,43) except
that a Superdex 200 26/60 (GE Healthcare) gel ﬁltration
column was included as the ﬁnal step.
Polyclonal antibodies against yPCNA were kindly
provided by Drs Satya Prakash and Stefan Jentsch.
Cdc9 polyclonal antibodies have been described
previously (44).
Surface plasmon resonance
yPCNA, pcna-79 or pcna–90 were immobilized on
a Biacore CM5 chip at comparable densities by
carbodiimide coupling according to the manufacturer’s
instructions. The running buﬀer contained 30mM
HEPES-NaOH (pH 7.5), 0.5mM EDTA, 10% glycerol,
0.1mM EDTA, 0.01% NP-40 and 150mM NaCl.
GST-Cdc9 wild-type, GST-Cdc9 PIP box mutant
(FF44,45AA) and FEN-1 (Rad27) were injected (100nM,
60ml total at 20ml/min) and monitored for association and
dissociation (response units, RU) as a function of time.
The surface plasmon resonance studies were carried out
on a Biacore 300 Biosensor in the Biacore Core Facility
of the University of Maryland School of Medicine.
GST pull-down assays
To prepare beads with GST, GST-Cdc9p or GST-Cdc9
PIP box mutant (FF44,45AA) as the ligand, 10mg of each
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Glutathione Sepharose beads (GE Healthcare) equili-
brated in binding buﬀer (50mM KH2PO4 (pH7.5),
10% glycerol, 150mM NaCl, 0.2% NP-40, 1mM
2-mercaptoethanol, and 1mg/ml bovine serum albumin
(BSA)) for 30min at 48C with constant agitation. After
washing with binding buﬀer, the beads were resuspended
in 100ml binding buﬀer. GST, GST-Cdc9p or GST-Cdc9
PIP box mutant beads (5pmol of each protein) were
incubated with 5pmol of wild-type yPCNA, pcna-79
or pcna-90at room temperature for 30min with constant
agitation. Beads were collected by centrifugation and then
washed extensively in binding buﬀer prior to being
resuspended in 10ml of sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis (PAGE) sample
buﬀer. After separation by SDS-PAGE, proteins were
detected by immunoblotting. Similar pull-down assays
with the GST fusion proteins described above were
performed with 5pmol of puriﬁed yRFC. After separation
by SDS-PAGE, proteins were detected by staining with
coomassie blue.
Preparation of biotin-labeled linear DNA substrate
This substrate was prepared as described previously (35).
Brieﬂy a 50 biotinylated 90 mer was annealed with two
complementary 15 mer to generate a partial duplex
of 30bp with a single nick in the middle ﬂanked by
single-strand regions of 30nt. For ligation assays, one
of the 15-mer oligonucleotides was 50 end-labeled with
[g
32P]ATP using T4 polynucleotide kinase to generate
a ligatable central nick.
DNA joining reaction with biotin-labeled linear DNA
substrate
DNA joining assays were carried out as described
previously (35). Streptavidin-agarose beads (10ml, Pierce)
were incubated with 1.6pmol of the biotinylated linear
DNA substrate in phosphate-buﬀered saline for 30min at
room temperature. After washing three times with ligation
buﬀer (50mM Tris-HCl (pH 7.5), 10mM MgCl2,
1mM dithiothreitol, 0.25mg/ml BSA and 1mM ATP),
the beads were incubated with 2pmol of E. coli single
strand binding (SSB) protein (Sigma) per pmol of DNA in
the same buﬀer for 15min at room temperature.
The beads liganded by SSB-coated DNA were washed
three times and ﬁnally resuspended in ligation buﬀer
containing 150mM NaCl. The binding of SSB to the
single strand ends of the partial duplex prevents PCNA
molecules loaded at the central nick from sliding oﬀ the
DNA. The SSB-blocked substrate (1pmol) was incubated
with 1pmol yRFC in the presence and absence of wild-
type yPCNA, pcna-79 or pcna-90 (1pmol trimer) at 308C
for 2min prior to the addition of Cdc9 (1pmol of either
wild-type or Cdc9 PIP box mutant). After incubation
at room temperature for 5min, the beads were spun down
and the reaction terminated by addition of 10mlo f
stop mix (10% glycerol, 0.2% SDS, 4mM EDTA
and 0.01% bromophenol blue) and heating at 1008C
for 3min to denature DNA. Aliquots (2ml) were mixed
with 2ml of denaturing PAGE dye (95% formamide,
0.05% bromophenol and 0.05% xylene cyanol) prior to
electrophoresis through a 12% denaturing polyacrylamide
gel. After drying, labeled oligonucleotides in the gel were
detected and quantitated by PhosphorImager analysis
(Molecular Dynamics).
Analysisof DNA–protein complexes
by streptavidin pull-down assays
The DNA substrate used in assays to detect DNA protein
complexes formed by yRFC, yPCNA and Cdc9 was
prepared as described above except for the absence of
a5 0 phosphate group at the central nick. The SSB-blocked
substrate (1pmol) was incubated in ligation buﬀer with
150 NaCl, with various combinations of yRFC, Cdc9
and wild-type and mutant versions of yPCNA for 15min
at 258C. The streptavidin beads were collected by
centrifugation and then washed twice with ligation
buﬀer containing 150mM salt. Bound proteins were
released from the beads by the addition of 10ml of SDS
sample buﬀer. After heating at 1008C for 3min, proteins
(5ml) were separated by SDS-PAGE and detected by
immunoblotting.
RESULTS
Structure of aCdc9 peptidebound toyPCNA
To characterize the binding interface between yPCNA
and Cdc9 DNA ligase, we determined the structure
of a complex between a peptide (32-AGKKPKQATLAR
FFTSMKNKPT-53, Figure 1A) encompassing the
PIP box (bold) of Cdc9 DNA ligase bound to yPCNA
(Pol30) to 2.8A ˚ resolution by X-ray crystallography
(Table 1). The structure contains one peptide bound to
one subunit of yPCNA in the asymmetric unit, which form
trimers through crystallographic symmetry (Figure 1B).
yPCNA exhibits a two-domain, a/b fold that is character-
istic of sliding clamp homologs (45) and closely resembles
the existing yPCNA structure (rmsd¼1.1A ˚ for 252 out
of the 255 comparable Calpha atoms) (18). Electron density
for the peptide was suﬃcient to model 11 residues
(35-KPKQATLARFF-45) that encompass the PIP box
(bold) and interact with both the IDCL and C-terminus of
yPCNA (Figure 2A). The side chains of peptide residues
Gln38, Leu41 and Phe44 were well deﬁned by the omit
electron density (Figure 2A), and used to anchor the
overall position of the peptide in the binding site. Peptide
residues with weaker side chain density (Phe45) were
modeled based on a combination of the electron density,
previous PCNA:peptide structures and biochemical data
(see Figure 5,7–8). The interactions between the Cdc9
peptide and the two regions of PCNA account for most of
the diﬀerences between the yPCNA:peptide complex
and the free yPCNA structure.
Similar to other PCNA-peptide structures, conserved
residues in the PIP-box of the Cdc9 peptide (LARFF)
adopt a helical conformation that positions the
hydrophobic residues on the same face of the helix.
This conserved structural motif (Figure 1A) acts as
a hydrophobic anchor that facilitates binding to the
surface of PCNA. The hydrophobic-binding site on
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(Leu126, Ile128) in the IDCL together with Val40,
Val45, and Leu47 from the N-terminal domain
(Figure 2). These residues are located at the inter-
domain interface of yPCNA (Figure 2A, 3) and provide
a conserved binding site for several proteins that interact
with PCNA (46,47).
As noted above, there are signiﬁcant diﬀerences
between the structures of the yPCNA:peptide and free
yPCNA (rmsd of 2.2A ˚ for the Calpha atoms of yPCNA
residues 121–132; Figure 4). In the yPCNA apo structure,
the IDCL region contacts the IDCL of neighboring
PCNA molecules in the crystal (18) whereas the Cdc9
peptide:yPCNA complex crystallizes in a diﬀerent space
group, in which the IDCL only contacts the Cdc9 peptide.
Thus, the yPCNA IDCL region exhibits structural
plasticity and becomes ordered due to interactions with
PIP box containing peptides (Figure 4A).
A structural comparison of human, yeast and archaeal
PCNA with PCNA complexes from the same organisms
shows that localized structural changes in PCNA are
signiﬁcant and well conserved (Figure 4). For example,
the structural diﬀerences between yPCNA:Cdc9 and
yPCNA are similar to those between yPCNA:yRFC and
yPCNA (Figure 4B and C). Comparison of human PCNA
and human PCNA complexes shows a similar trend
(Figure 4D and F). In general, most of the structural
diﬀerences greater than 2A ˚ (between identical Calpha
atoms in each structure) are localized to the IDCL and
the C-terminal tail of PCNA. Structural changes in
solvent-exposed loops, and in residues at the trimer
interface are also observed, consistent with recent results
highlighting the ﬂexible nature of interactions among
PCNA subunits (48). Notably, yPCNA from our
yPCNA:Cdc9 peptide complex is more similar to
yPCNA from the yRFC:yPCNA complex than to yPCNA
from either complex compared to the unbound structure
of yPCNA (Figure 4A–C), suggesting that conserved
structural changes occur in PCNA when enzymes associ-
ate with PCNA via the conserved PIP motif.
In addition to the conserved hydrophobic-anchor
motif (Figure 1A), residues near the N-terminus of the
Cdc9 peptide (KQA) form a b-sheet with residues in
the C-terminal domain of yPCNA (Figures 2 and 3A).
The b-sheet backbone interactions are supplemented by
Figure 1. Crystal structure of yPCNA complexed with a Cdc9 peptide
encompassing the PIP box. (A) Cdc9 peptide sequence used for
crystallization showing the secondary structure of residues observed in
the co-crystal structure (bold black letters) in relation to disordered
residues (gray letters) that had no observed electron density. The Cdc9
peptide is aligned with the PIP box and surrounding residues from
human DNA ligase I (hDNA Lig I), yeast Rfc-1 (Rfc1), yeast FEN-1
(Rad27) and yeast Pol d (Pol32). The starting and ending residue
numbers, along with the total sequence length is shown for each
protein. Key residues of the PIP box are denoted by asterisks (*) below
the sequence. (B) Structure of the Cdc9 peptide:yPCNA complex shown
as a trimer based on crystallographic symmetry. The yPCNA trimer
is shown as a ribbon (subunits colored beige, blue and pink) with
colored spheres marking the position of mutant residues in the pcna-79
(blue spheres) and pcna-90 (red spheres) mutants. The Cdc9 peptide
(green) is bound to each of the subunits.
Table 1. X-ray diﬀraction data and reﬁnement statistics
X-ray diﬀraction data PCNA:Cdc9 peptide
Wavelength (A ˚ ) 0.9790
Space group I23
Resolution (A ˚ ) 40-2.8 (2.9-2.8)
Observations 35,241
Unique reﬂections 11,287 (1,104)
Completeness (%) 99.2 (99.2)
Rsym
a (%) 3.9 (41.8)
Wilson B-factor (A ˚ 2)9 4
Model reﬁnement
Resolution (A ˚ ) 30-2.8







Number of PCNA atoms
d 2003 (38)
Number of peptide atoms
d 92 (40)
Number of solvent atoms
d 17 (70)
Values in parentheses indicate the high-resolution shells, unless
otherwise noted.
aRsym¼h i | I(h,i) 5I(h)4|/h i I(h,i), where I(h,i) is the intensity
of the i th measurement of reﬂection h and5I(h)4is the average value
over multiple measurements.
bRcryst¼||Fo| |Fc||/|Fo| for all reﬂections (no   cutoﬀ), where Fo
and Fc are the observed and calculated structure factors, respectively.
cRfree was calculated as Rcryst against 5% of the reﬂections removed at
random.
dValues in parentheses indicate the average B-factor (A ˚ 2).
1628 Nucleic Acids Research, 2007, Vol. 35, No. 5two additional hydrogen bonds formed between the side
chain of Gln38 and the peptide backbone of both Cdc9
and PCNA (Figure 2B). The side-chain of Gln38 (N")
within the Cdc9 peptide forms a hydrogen bond with the
carbonyl oxygens of Ala251 from yPCNA and Ala39 from
the Cdc9 peptide (Figure 2B). These interactions appear
to stabilize the b-sheet and compensate for the presence
of the conserved Pro252, which would otherwise disrupt
continuous hydrogen bond interactions between the
peptide backbones of Cdc9 and yPCNA.
The b-sheet interactions observed in the yPCNA:Cdc9
peptide complex are almost identical to those observed in
the structure of human FEN-1 bound to human PCNA
(26) and similar to those observed in structures of FEN-1
peptides bound to archaeal PCNA (32). It should be noted
that the b-sheet formed between the FEN-1 peptide and
the C-terminus of archael PCNA was slightly longer
than the similar structures in the complexes formed
by eukaryotic PCNA. This may reﬂect diﬀerences in the
size of archaeal and eukaryotic PCNAs, in particular the
C-terminal domain of archaeal PCNA is shorter than that
of eukaryotic PCNA (26,32,49) (Supplementary Figure 1).
For example, the shorter archaeal PCNA lacks two of the
three residues at the C-terminal end of yPCNA (residues
256–258) that fold back to form a hairpin in the apo
structure of yPCNA and interact with the same PCNA
residues (residues 252–255) contacted by the Cdc9 peptide
(Figure 3B). In the presence of the Cdc9 peptide, the
three C-terminal residues of yPCNA (residues 256–258)
are disordered (no observed electron density), and the
peptide occupies the b-sheet binding interface (Figure 3).
Although many studies on PCNA interacting proteins
have focused on interactions with the IDCL of PCNA
(46,47), there is emerging evidence that regions adjacent
to the PIP box are involved in functionally important
contacts with the C-terminal domain of PCNA
(31,32,50,51). While the functional role of the b-zipper
interaction is not completely understood, the formation
of the same structure with peptides from both FEN-1 and
Cdc9 DNA ligase, suggests that it plays a key functional
Figure 2. Structure of the PCNA:Cdc9 interface. (A). Stereo view showing omit Fo-Fc electron density for the Cdc9 peptide (green carbons, red
density contoured at 2.5  calculated by omitting the peptide residues) and the C-terminal residues of PCNA (251–255; orange carbons, blue density
contoured at 2.5  calculated by omitting residues 251–255 from the model). The omit density shows the general position of the peptide backbone and
most side chains for both the peptide and C-terminus of PCNA. The side chains of peptide residues Gln38, Leu41 and Phe44 were well deﬁned by
the omit electron density, and used to anchor the overall position of the peptide in the binding site. However, no density was observed for the side
chains of peptide residues Lys 35 and Lys 37, and only weak density was observed for the Phe 45 side chain. These residues were modeled based on
a combination of the electron density, previous PCNA:peptide structures, and biochemical data. In addition to interactions with residues near the
C-terminus of PCNA, Cdc9 binds to a hydrophobic pocket formed by several PCNA residues (cyan) surrounding the IDCL (Leu126, Ile128).
(B). Schematic showing hydrogen bonds and hydrophobic interactions between residues near the C-terminus of PCNA (orange) and residues from
the Cdc9 peptide (green). Several hydrogen bonds (dotted lines) form between the peptide backbones of Pro252, Lys253 and Phe254 with peptide
residues Lys37, Gln38 and Ala39. The side chain of Gln38 also forms hydrogen bonds with Ala251 from PCNA and Ala39 from Cdc9. Residues
from the hydrophobic pocket on PCNA (black box) form hydrophobic interactions (black lines with arrows) with Leu41, Phe44 and Phe45, located
on the 310 in the Cdc9 peptide. Residues with no observed electron density are listed inside boxes with dash-line borders.
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proteins.
In the case of yeast FEN-1 (Rad27), the interaction with
the IDCL of yPCNA is required for complex formation in
the absence of DNA whereas the C-terminal residues
of PCNA involved in formation of the b-zipper are
critical for the stimulation of the DNA structure-speciﬁc
endonuclease activity of FEN-1 (Rad27) (29,31,34).
This prompted us to examine the roles of the IDCL
and C-terminal interfaces of PCNA on physical and
functional interactions with Cdc9 in the absence or
presence of DNA.
Interaction between Cdc9 and PCNA inthe absence ofDNA
To determine the contribution of the IDCL region of
yPCNA to Cdc9 binding, we used pcna-79, a mutant in
which Leu126 and Ile128 are substituted with alanine.
These residues are located in the IDCL and form the
hydrophobic pocket on yPCNA that binds the hydro-
phobic anchor motif formed by PIP box residues of Cdc9
(Figures 2 and 3). The IDCL mutations severely disrupt
Cdc9 binding to pcna-79 as measured both by surface
plasmon resonance (Figure 5A and B) and GST pull-down
assays (Figure 5C, compare lanes 7 and 8). In addition,
we also replaced the conserved phenylalanine residues
(F44F45) in the PIP box of Cdc9 with alanine residues.
Based on the Cdc9 peptide:yPCNA structure,
these residues interact directly with the conserved
hydrophobic-binding site that is disrupted in the pcna-79
mutant. Consistent with the complex structure
(Figures 1–4) and previous biochemical studies (25),
substitution of these PIP box residues in Cdc9 also
reduced complex formation with yPCNA (Figure 5B and
C, compare lanes 7 and 10). Notably, changes in the
PIP box of Cdc9 had a much lesser eﬀect on the
interaction between Cdc9 and yPCNA compared with
changes in the IDCL of yPCNA. In contrast, replacement
of the adjacent phenylalanine residues in the FEN-1
(Rad27) PIP box had a slightly more severe impact on the
interaction between PCNA and FEN-1 compared with the
amino changes in the IDCL of yPCNA (31).
It should be noted that, in the FEN-1 (Rad27) study
described above (33), the conserved adjacent Phe residues
in the PIP box were replaced with Gly and Ala whereas,
in the Cdc9 PIP box, they were replaced with two Ala
residues. The energetic diﬀerence between burying an Ala
or a Gly at this interface is not signiﬁcant compared
with the loss of the Phe side chain (52). However, Gly is
known to interfere more with helical stability compared to
Ala. Thus, the diﬀerences in the interactions of residues
surrounding the PIP boxes of FEN-1 and Cdc9 with
yPCNA might underlie the diﬀerences observed following
the replacement of the conserved Phe residues in the
PIP boxes of Cdc9 and FEN-1. For example, the interface
between human FEN-1 and PCNA extends beyond both
sides of the PIP box to include b-sheet interactions with
both the C-terminus and the IDCL of human PCNA (26).
In contrast, the structure of the Cdc9 peptide:yPCNA
complex does not show additional interactions with the
IDCL beyond the PIP box. Disruption of the helical
structure that positions the Phe residues would also
disrupt the positioning of FEN-1 residues following the
mutation amplifying the aﬀect of the Phe substitutions
in FEN-1 (Rad27).
An alternative explanation for this diﬀerence in
mutational results is the presence of additional PCNA
interactions between Cdc9 and PCNA that do not involve
the N-terminal PIP Box of Cdc9. A recent structure of
a DNA Ligase I homolog from Sulfolobus solfataricus
identiﬁed a PIP box located in the DNA-binding domain
(53). Whilst the DNA binding domains of hLig1 and Cdc9
do not contain a canonical PIP-box, further binding
experiments revealed an additional weak interaction
between PCNA and DNA binding domain of human
DNA Ligase I (hLig1) (53). If the IDCL and C-terminal
tail of yPCNA also interact weakly with the DNA-binding
domain of Cdc9, then mutations in yPCNA would aﬀect
both interfaces. Thus, mutations in yPCNA would have
a greater eﬀect on the interaction between Cdc9 and
yPCNA than mutations in the PIP box of Cdc9.
To determine the contribution of the C-terminal region
of yPCNA to Cdc9 binding, we used pcna-90, a mutant in
which Pro252 and Lys253at the base of the C-terminal
tail of yPCNA are substituted with alanine. Surprisingly,
these changes severely disrupted binding of Cdc9 to
pcna-90 as measured by surface plasmon resonance
(Figure 5A and B) and GST pull-down assays
(Figure 5C, compare lanes 7 and 9). Thus, amino acid
changes in the IDCL and C-terminal domain of yPCNA
Figure 3. Interface exchange at the C-terminus of PCNA. (A). Cdc9
peptide fold (green) bound to PCNA (beige and orange) shown
as ribbons indicating that the N-terminus of the Cdc9 peptide forms a
b-sheet with the PCNA C-terminus (orange). Conserved hydrophobic
residues (green, labeled) interact with a hydrophobic pocket on
the surface of PCNA (blue side chains). (B). The location of the
Cdc9 peptide (dotted black outline) relative to the structure of PCNA
determined without a peptide (PCNA apo; PDB code 1PLQ). Without
bound peptide, the C-terminus of PCNA (orange) loops back to
interact with itself by forming a tight turn. Binding of the Cdc9 peptide
(dotted outline) exchanges the PCNA intra-molecular beta-turn
structure with an inter-molecular b-sheet interface (A and B) formed
by residues at the N-terminus of the Cdc9 peptide hydrogen bonding
to residues near the C-terminus of PCNA.
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(Figure 5), demonstrating that Cdc9, unlike FEN-1
(Rad27), requires interactions with both the IDCL and
C-terminal domain interfaces of yPCNA to form
a complex in the absence of DNA.
InteractionbetweenCdc9andPCNAinthepresenceofDNA
To determine the contributions of the IDCL and
C-terminal regions of PCNA to Cdc9 binding in the
presence of DNA, we used yRFC to load wild-type
and mutant versions of PCNA onto biotinylated
DNA substrates with blocked ends (Figure 6A). In initial
experiments using a ligatable substrate, we were unable to
detect Cdc9 binding to yPCNA on the DNA-streptavidin
beads (data not shown), presumably because Cdc9 rapidly
dissociates from the DNA after ligation. Using a non-
ligatable DNA substrate (Figure 6B), we found that,
as expected, yPCNA was only retained by the DNA beads
after loading by yRFC (Figure 6B, compare lanes 2–4 with
lanes 6–8) and that Cdc9 binding to the beads was barely
detectable in the absence of loaded yPCNA (Figure 6B,
lanes 1 and 9–11). In accord with the results of studies
with the functionally homologous human proteins (27),
Cdc9 was retained by the beads when wild-type yPCNA
was topologically linked to the DNA molecule (Figure 6C,
lanes 2–4). A similar amount of Cdc9 was retained by the
DNA beads when yRFC was removed from the reaction
after PCNA loading and prior to incubation with Cdc9
(data not shown), indicating that yRFC does not inﬂuence
complex formation between yPCNA and Cdc9 on DNA
under these conditions. The amount of bound Cdc9 was
markedly reduced in assays with pcna-90 (Figure 6C,
compare lanes 2–4 with 8–10), but not with pcna-79
(Figure 6C, compare lanes 2–4 with 5–7). Increasing the
concentration of PCNA did not increase the amount of
Cdc9 bound to the beads and, in fact reduced the amount
retained in assays with the mutant versions of yPCNA.
Together, these results demonstrate that the interaction
between Cdc9 and the C-terminal domain of yPCNA
plays a major role in complex formation both on and
oﬀ DNA.
Aconserved physical and functional interaction between the
replicative clamp loader and DNA ligase ofeukaryotes
Previously we showed that human DNA ligase I binds
directly to human RFC (35). To determine whether
Figure 4. Structural changes caused by binding to PCNA. PCNA
subunits from structure of PCNA:peptide or PCNA:enzyme complexes
were aligned with structures of the apo form of PCNA from the same
organism. The distance between Ca residues for each pair of structures
is shown mapped onto the structure of PCNA as both a color gradient
and ribbon thickness. The distances were sorted as a histogram with
0.2A ˚ bins ranging from 0A ˚ (blue, thin ribbon) to  3.0A ˚ (red, thick
ribbon) as indicated by the scale bar in the bottom section. The PDB
codes for the structures used in each comparison are shown in
parentheses, along with the RMSD values for each comparison.
The majority of the diﬀerences are localized to ﬂexible loop regions,
with minor diﬀerences in the helices that contact DNA. Both the inter-
domain connecting loop (IDCL), as well as the C-terminal tail make up
a large proportion of the structural changes. These regions form the
structural interface responsible for binding the conserved PIP-motif
(green region) found in several enzymes that interact with PCNA.
(A) Yeast PCNA (yPCNA):Cdc9 peptide complex compared to the
yRFC:yPCNA complex (1SXJ). (B) yPCNA:Cdc9 peptide complex
compared to apo yPCNA (1PLQ). (C) yPCNA:yRFC complex (1SXJ)
compared to apo yPCNA (1PLQ). (D) human PCNA (hPCNA):p21
peptide complex (1AXC) compared to apo hPCNA (1VYM).
(E) Archaeoglobus fulgidus PCNA (aPCNA): A. fulgidus FEN-1
(aFEN-1) peptide complex (1RXZ) compared to apo aPCNA
(1RWZ). (F) hPCNA:human FEN-1 complex (1UL1) compared to
apo hPCNA (1VYM).
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homologous yeast proteins, we immobilized GST-fusions
of wild-type and mutant versions of Cdc9 on glutathione
beads and assayed for retention of puriﬁed, recombinant
yRFC. In these pull-down assays, yRFC bound speciﬁ-
cally to beads liganded by wild-type GST-Cdc9
(Figure 7A, lane 3). Moreover, replacement of the
adjacent phenylalanine residues in the Cdc9 PIP box
with alanine residues that disrupted binding with yPCNA
(Figure 5) had no signiﬁcant eﬀect on the interaction with
yRFC (Figure 7A, lane 4), suggesting that Cdc9 binds
to yRFC and yPCNA via diﬀerent interfaces.
Next we asked whether yRFC modulates the activity
of Cdc9 in the presence or absence of PCNA. yRFC
inhibited the joining of a central nick within a linear DNA
duplex (35) by Cdc9 DNA ligase (Figure 7B, compare
lanes 2 and 3) whereas yPCNA had no eﬀect (Figure 7B,
compare lanes 2 and 5). Notably, co-incubation of yPCNA
with yRFC abolished the inhibitory eﬀect of yRFC
(Figure 7B,lanes 2–4) butonly whenCdc9 hadafunctional
PIP box (Figure 7C). In assays with the ATP analog,
ATPgS, which cannot be hydrolyzed by RFC but can
be used as a co-factor by Cdc9 DNA ligase, RFC still
inhibits Cdc9, but the inclusion of PCNA does not
alleviate this inhibition (data not shown). This suggests
that PCNA loading by RFC and/or the dissociation
of the RFC/PCNA complex following loading is also
necessary to recover DNA joining activity. The results
shown in Figure 7 recapitulate those obtained with the
functionally homologous human proteins (35), indicating
that the physical and functional interactions among the
replicative DNA sliding clamp, clamp loader and DNA
ligase are conserved among eukaryotes.
Both theIDCL region and C-terminal domain of yPCNA
are importantfor thefunctional interplay among Cdc9,
yRFC and yPCNA
The results of studies with the functionally homologous
human (35) and yeast proteins (Figure 7) have shown that
the PCNA-dependent recovery of DNA joining activity
requires adjacent phenylalanine residues within the
PIP box of the DNA ligase. If the physical interaction
between the Cdc9 PIP box and the IDCL of yPCNA is
critical for the functional interplay among yRFC, yPCNA
and Cdc9 DNA ligase, then amino acid changes within the
IDCL of yPCNA that disrupt the binding with the Cdc9
PIP box should have a similar eﬀect to inactivation of the
Cdc9 PIP box. In accord with this prediction, the mutant
version of yPCNA, pcna-79 that contains amino acid
substitutions of key residues within the IDCL was unable
to completely restore DNA joining in the presence of
Figure 5. Interaction of Cdc9 with wild-type and mutant versions of PCNA in the absence of DNA. (A). Schematic of sensor chip used in surface
plasmon resonance analysis of association of Cdc9 with PCNA. PCNA wild-type PCNA (P-W), pcna-79 (P-79) and pcna-90 (P-90) were immobilized
to a CM5 chip and 100 nM of GST fused to either wild-type Cdc9 (Wt) or Cdc9 FF44,45AA mutant (PIP box Mut) were passed over the chip.
(B). Sensorgram showing the association and disassociation curves of GST-Cdc9 wild-type (C-W) with PCNA wild-type (P-W/C-W), pcna79
(P-79/C-W) and pcna-90 (P-90/C-W) and of GST Cdc9 FF44,45AA mutant (PIP box Mutant; C-M) with PCNA wild-type (P-W/C-M),
pcna79 (P-79/C-M) and pcna-90 (P-90/C-M). (C) Pull-down assays. Lanes 1–3 represent 10% of input PCNA used in the pull-down assay. Puriﬁed
PCNA (P-W), pcna-79 (P-79) and pcna-90 (P-90) (5pmol of PCNA trimer) were incubated with glutathione sepharose beads liganded by 5pmol of
GST, GST–Cdc9 wild-type (GSTCdc9 Wt) or GST-Cdc9-PIP box mutant (GST Cdc9 PIP Mut). Proteins bound to GST beads (lanes 4–6),
GST–Cdc9 Wt beads (lanes 7–9) and GST–Cdc9p PIP Mut beads (lanes 10–12) were separated by SDS-PAGE. PCNA (top panel) and GST-Cdc9p
(bottom panel) were detected by immunoblotting with Cdc9 and PCNA antibodies, respectively.
1632 Nucleic Acids Research, 2007, Vol. 35, No. 5Figure 6. Interaction of Cdc9 with PCNA topologically linked to duplex DNA. (A). Schematic illustration of the assay. Streptavidin beads bound by
biotinylated, non-ligatable nicked DNA molecules with blocked ends were prepared as described in materials and methods section. PCNA was
loaded onto the DNA by incubation with RFC and then Cdc9 was incubated with the PCNA/DNA complexes. (B). The DNA substrate (1pmol)
was incubated with 1pmol of each of the following proteins; RFC (R), wild-type PCNA (P-w), pcna-79 (P-79) pcna-90 (P-90) and wild-type Cdc9
(C-w) either alone or in the combinations indicated. (C). The DNA substrate (1pmol) and RFC (1pmol) were incubated with; wild-type PCNA (W),
lane 2, 1pmol; lane 3, 2pmol; lane 4, 3pmol; pcna-79 (79), lane 5, 1pmol; lane 6, 2pmol; lane 7, 3pmol; and pcna-90 (90), lane 8, 1pmol; lane 9,
2pmol; lane 10, 3pmol; for 1min followed by the addition of wild-type Cdc9 (1pmol) and further incubation for 15min at room temperature.
After centrifugation to collect the DNA beads, the speciﬁc retention of PCNA and Cdc9 by the beads was detected by immunoblotting.
Figure 7. Interaction between Cdc9 and yRFC. Eﬀect of yRFC and yPCNA on the DNA joining activity of Cdc9. (A). Puriﬁed yRFC (0.5pmol)
complex was incubated with glutathione sepharose beads liganded by; lane 2, GST; lane 3, GST fused to wild-type Cdc9 (GST-Cdc9-Wt); and lane 4,
GST fused to the PIP box mutant version of Cdc9 (GST-Cdc9 PIP box mutant). Proteins bound to the beads were separated by SDS-PAGE gel and
then stained with coomassie blue. Lane 1 contains 5% of the RFC input. The positions of bands corresponding to GST, the GST-Cdc9 fusion
proteins, the large subunit of yRFC (RFC1) and the four small yRFC subunits (RFC2-5) are indicated on the right. (B). The linear end-blocked
DNA substrate (1pmol) was incubated as described in materials and methods section with equimolar ratios (1pmol) of yRFC (R), yPCNA (P) and
wild-type Cdc9 (Cw). (C). The linear end-blocked DNA substrate (1pmol) was incubated as described in experimental procedures section with
equimolar ratios (1pmol) of yRFC (R), yPCNA (P) and a mutant version of Cdc9 with a defective PIP (Cm) as indicated. Labeled oligonucleotides
were separated by denaturing PAGE and quantitated by PhosphorImager analysis (molecular dynamics). The positions of labeled 15-mer
substrate and 30-mer product are indicated on the right of a representative gel (left panel). The results of three independent experiments are shown
graphically (right panel).
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pcna-79 mutant, ligation eﬃciency was reduced to 25%
of that in comparable assays with wild-type Cdc9
(Figure 8A, compare lanes 4 and 5).
Our analysis of complex formation between Cdc9
and yPCNA revealed that an interaction between the
C-terminal domain of PCNA and amino acid residues
adjacent to the Cdc9 PIP box is required for complex
formation both in the absence (Figure 5) and presence
of DNA (Figure 6). Therefore, we examined the activity
of pcna-90 that contains amino acid substitutions in
C-terminal residues required for complex formation
with Cdc9 in DNA-joining assays containing yRFC.
At equimolar ratios of yRFC and the pcna-90 mutant,
ligation eﬃciency was reduced to  10% of that in
comparable assays with wild-type Cdc9 (Figure 8, lanes
4–6). Taken together these results show that interactions
with both the IDCL and C-terminal regions of yPCNA
are required for Cdc9 to overcome inhibition by yRFC.
Given the large number of PIP-box-containing proteins,
it appears likely that the PIP box/IDCL interface may
serve as the primary docking site that in turn facilitates
interactions between other regions of PCNA and its
partner proteins. If Cdc9 binding to the IDCL promotes
functional contacts with the C-terminus of PCNA, then
increasing the amount of the PCNA with a defective
IDCL should overcome the requirement for the initial
binding step. In accord with this model, when the molar
ratio of pcna-79 to Cdc9 was increased from 1:1 to 3:1,
the amount of DNA joining was almost restored to the
levels observed with a wild-type yPCNA: Cdc9 ratio of
1:1 (Figure 8B). The pcna-90 mutant version is more
defective in complex formation with Cdc9 when
topologically linked to DNA and in alleviating inhibition
by RFC compared with pcna-79, suggesting that forma-
tion of the b-zipper between Cdc9 and yPCNA plays a
critical role in positioning Cdc9 on the yPCNA ring
during the functional interplay with yRFC. This scenario
predicts that increasing the amount of pcna-90 will be less
eﬀective in overcoming inhibition by yRFC compared
with pcna-79. In accord with this model, DNA joining was
still markedly inhibited, at a 3:1 ratio of pcna-90: Cdc9
(Figure 8B). Thus, our results have shown that the Cdc9
PIP box region makes critical contacts with both the
IDCL and C-terminus of yPCNA and strongly suggest
that these two protein–protein interfaces have distinct
functional roles.
DISCUSSION
PCNA plays a central role in DNA metabolism via
interactions with a large number of proteins involved
in diﬀerent DNA transactions and cell cycle regulation
(reviewed in (16,23)). For example, the action of enzymes
involved in the DNA synthesis, end processing and
ligation steps during the maturation and joining of
Okazaki fragments and completion of certain DNA
excision repair pathways are coordinated by protein–
protein interactions with PCNA. Many PCNA interacting
proteins contain a conserved PIP box motif that interacts
with the IDCL of PCNA (47). Crystal structures of PCNA
complexed with PIP box peptides from several PCNA
interacting proteins have shown that the highly conserved
residues of the various PIP boxes make remarkably similar
interactions with PCNA in the form of a 310 helix that
interacts with the hydrophobic residues of the IDCL of
PCNA (19,32,49,54). Since PIP-box-containing proteins
bind to the same site on PCNA, the key question is how
the interactions with diﬀerent PCNA-binding proteins
are regulated and co-ordinated. There is emerging
evidence from the structural studies that the amino acid
sequences adjacent to the PIP box contribute to the
aﬃnity and speciﬁcity of the protein–protein interaction
by contacting diﬀerent regions of PCNA (19,32,49).
For example, the residues C-terminal to the PIP box of
the cyclin-dependent protein kinase inhibitor p21 forms
a b-sheet with the IDCL of PCNA and contribute to the
high aﬃnity interaction between p21 and PCNA (19,49).
However, the functional and biological signiﬁcance of
protein–protein interactions involving amino acid
sequences adjacent to the PIP box in PCNA-binding
proteins have not been demonstrated unequivocally.
In this study, our structural, biochemical and mutational
results demonstrate that the PIP box region of Cdc9
contacts two distinct regions of yPCNA and that both of
these protein–protein interfaces are critical for physical
and functional interactions between Cdc9 and PCNA.
The structure of yPCNA complexed with a peptide
encompassing the Cdc9 PIP box revealed that, in addition
to the contacts made by conserved residues within the
Cdc9 PIP box, amino acid residues N-terminal of the
PIP box interact with residues within the C-terminus
of PCNA to form a b-zipper structure. A similar structure
Figure 8. Amino acid residues within both the IDCL and C-terminus of
PCNA are required to overcome RFC-mediated inhibition of Cdc9.
(A). DNA-joining reactions were carried out as described in the legend
of Figure 5 except that pcna–79 (79) and pcna-90 (90) were included
in addition to wild-type PCNA (W) as indicated. Left panel,
a representative gel and, right panel, a bar graph show the results of
three independent experiments. (B). DNA-joining assays with RFC
(1pmol) and Cdc9 (1pmol) and increasing amounts of wild-type PCNA
(P-W) and the mutant versions of PCNA, pcna–79 (P-79) and pcna-90
(P-90), were carried out as described in the legend to Figure 5 and
are shown graphically.
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human PCNA (26) and in the complex formed by
an archaeal FEN-1 peptide and archaeal PCNA (32).
Deletion analysis of the C-terminus of human PCNA has
shown that whilst the 5 terminal residues (equivalent to
residues 256–258 in yPCNA) are not required for physical
and functional interactions with FEN-1, removal of
the 8 terminal residues (equivalent to residues 253–258
in yPCNA) caused substantially reduced stimulation of
FEN-1 activity by PCNA but had no aﬀect on FEN-1
binding aﬃnity for PCNA (26) (Supplementary Figure 1).
Moreover, substitution of residues in the C-terminus of
yPCNA that are involved in b-zipper formation result in
hypersensitivity to hydroxyurea, MMS and UV light,
and a defect in DNA-dependent physical and functional
interactions between FEN-1 and PCNA (31,50). Thus,
our results demonstrating that the same C-terminal
residues of yPCNA are critical for physical and functional
interactions with Cdc9 provide further evidence that the
b-zipper structure is biologically signiﬁcant.
Since the action of the DNA-processing enzyme FEN-1
generates the ligatable nick for Cdc9 DNA ligase during
Okazaki fragment processing, a comparison of how these
enzymes interact with PCNA should provide insights
into the mechanisms by which PCNA co-ordinates
the sequential action of these enzymes. Although the
structures of peptides containing the PIP box of Cdc9
(Figures 1–4) and FEN-1 (34) complexed with PCNA
reveal similar protein–protein interfaces involving both
the IDCL and the C-terminal domain of PCNA
(Figure 3), there are diﬀerences in the contributions of
the two PCNA interaction interfaces to protein–protein
interactions with FEN-1 and Cdc9 in the presence and
absence of DNA. The IDCL of yPCNA is critical for
complex formation with FEN-1 in the absence of DNA
whereas FEN-1 binding to and stimulation by yPCNA
topologically linked to DNA are dependent upon residues
within the C-terminal domain of yPCNA (31). In contrast,
the IDCL and the C-terminal domain interaction
interfaces of yPCNA are each required for Cdc9 binding
to yPCNA, both unlinked and when topologically linked
to DNA, and for functional interactions among yRFC,
yPCNA and Cdc9.
Because of the trimeric structure of the PCNA ring,
it is possible that up to three proteins can bind
simultaneously to the PCNA ring via the IDCL of the
three PCNA monomers. Notably, the complex of human
FEN-1 and PCNA that formed crystals contained
3 molecules of FEN-1 and 3 molecules of PCNA
monomers with each FEN-1 molecule adopting a diﬀerent
conformation relative to the PCNA monomer (26).
This suggests that FEN-1 is ﬂexibly tethered to the
PCNA ring and that, when a single intact FEN-1 molecule
binds to a PCNA trimer, the IDCL-binding sites in the
other two subunits of the PCNA trimer are potentially
available for binding to other partners (26,32). In this
scenario, the PCNA sliding clamp acts as a toolbelt
and coordinates the actions of diﬀerent proteins by
holding them together on the same ring, thereby allowing
them to engage the appropriate DNA substrate. Recent
computational results suggest that PCNA associates
with DNA asymmetrically, such that one PCNA subunit
interacts speciﬁcally with the DNA minor groove,
consistent with coordinated interactions among PCNA-
binding partners that engage DNA (55). This type of
mechanism appears to underlie the ability of translesion
DNA polymerases to copy past a lesion that has stalled
the replicative polymerase/clamp complex and then permit
the replicative polymerase to re-engage on the undamaged
template (56). A similar mechanism may also explain
the eﬃcient co-ordination of Pol d and FEN-1 (Rad27)
activities during Okazaki fragment processing (57).
In contrast, the complexes formed between human
DNA ligase I and a DNA-linked PCNA trimer contained
1 molecule of DNA ligase I per PCNA trimer (27).
Moreover, experiments with puriﬁed yFEN-1, yPCNA
and Cdc9 have failed to detect PCNA complexes contain-
ing both FEN-1 and Cdc9 (25). These results strongly
suggest that the binding of the replicative DNA ligase to
a PCNA monomer within the PCNA trimer occludes
the two unoccupied IDCL-binding sites within the PCNA
ring. The notion that the binding of Cdc9 to PCNA
prevents interactions with other PCNA-binding proteins
is further supported by the observation that the induction
of genetic instability by overexpression of Cdc9 does not
require Cdc9 catalytic activity but instead is dependent
upon a functional PIP box (25).
Biophysical and biochemical studies of Cdc9 DNA
ligase and human DNA ligase I have shown that these
proteins have a very asymmetric shape and that their
non-catalytic N-terminal regions containing the
PIP box are very sensitive to proteolysis (28,44).
This suggests the N-terminal PIP box of the replicative
DNA ligase resides within a ﬂexible, unstructured region.
When complexed with nicked DNA, the catalytic domain
of human DNA ligase I forms a ring structure that is
similar in size and shape to the PCNA ring and also
encircles the DNA duplex (28). Thus, it is logical to
hypothesize that the initial docking of the DNA ligase
with a PCNA trimer via its PIP box region, which retains
DNA ligase in its elongated form (53), is then promoted
by PCNA association with DNA to form a ring structure
that may involve more extensive contacts with the surface
of the PCNA ring. Thus, multiple modular interactions
between PCNA and DNA ligase may be important for
function. Surprisingly, we and others have observed
that PCNA does not stimulate the catalytic activity of
the replicative DNA ligase (11,27,33,35). Thus, in addition
to the diﬀerences in the stoichiometry of the complexes
formed by FEN-1 and the replicative DNA ligase with
PCNA, these interactions do not have the same eﬀect
on catalytic activity. We suggest that the DNA ligase
interaction with PCNA blocks interactions with other
PCNA-binding proteins because it is the last step in
Okazaki fragment joining and DNA repair whereas
interactions with proteins acting earlier in these multi-
step pathways will involve a handover to the next protein.
Interestingly, there is a conserved interaction between
the replicative DNA ligase and RFC, the loader of the
PCNA sliding clamp (35). Although RFC inhibits DNA
joining, the presence of PCNA alleviates this inhibition.
This interplay among RFC, PCNA and the replicative
Nucleic Acids Research, 2007, Vol. 35, No. 5 1635DNA ligase is conserved and is dependent upon the
physical interaction between the PIP box region of the
DNA ligase and both the IDCL and C-terminal domain
of PCNA. If RFC and Cdc9 recognize parts of a common
interface on PCNA, then partner handoﬀs might be
mediated by exchange of a common structural motif, such
as the b-zipper, which resembles the Rad51 interface
exchange between BRCA2 binding and ﬁlament assembly
(59). Based on the horseshoe shape of RFC and the
multiple contacts between the DNA ligase and the RFC
subunits (35,58), we suggest that RFC may hold the DNA
ligase in a C-shaped structure and then deliver the
DNA ligase to PCNA rings at DNA nicks.
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